Ian Kirven, PT, DPT | |
1156 N Main St, Sheridan, WY 82801-3055 | |
(307) 763-4556 | |
Not Available |
Full Name | Ian Kirven |
---|---|
Gender | Male |
Speciality | Physical Therapy |
Experience | 10 Years |
Location | 1156 N Main St, Sheridan, Wyoming |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093115602 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | PT-1545 (Wyoming) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Hand Therapy Of Wyoming Llc | 7416233259 | 14 |
News Archive
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.
ExonHit Therapeutics (Paris:ALEHT) together with Toulouse University Hospital and l'Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT). The study's main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of cognitive functions in aged and frail individuals.
With the increasing demand for non-surgical aesthetic procedures, the FDA's recent clearance of an ultrasound device to tighten sagging skin has come as great news to consumers, especially those in Southeast Michigan, home to one of the first of these Ulthera Systems in the nation.
A dramatic sea-change in research into ten so-called "neglected diseases," such as malaria, leprosy and sleeping sickness, could result in at least eight new drugs being developed by 2010.
› Verified 4 days ago
Provider Name | Hand Therapy Of Wyoming Llc |
---|---|
Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
Provider Identifiers | NPI Number: 1083155972 PECOS PAC ID: 7416233259 Enrollment ID: O20170411000826 |
News Archive
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.
ExonHit Therapeutics (Paris:ALEHT) together with Toulouse University Hospital and l'Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT). The study's main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of cognitive functions in aged and frail individuals.
With the increasing demand for non-surgical aesthetic procedures, the FDA's recent clearance of an ultrasound device to tighten sagging skin has come as great news to consumers, especially those in Southeast Michigan, home to one of the first of these Ulthera Systems in the nation.
A dramatic sea-change in research into ten so-called "neglected diseases," such as malaria, leprosy and sleeping sickness, could result in at least eight new drugs being developed by 2010.
› Verified 4 days ago
Provider Name | Brandon Kelley Dc Pc |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1831675479 PECOS PAC ID: 2163811779 Enrollment ID: O20211118002937 |
News Archive
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.
ExonHit Therapeutics (Paris:ALEHT) together with Toulouse University Hospital and l'Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT). The study's main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of cognitive functions in aged and frail individuals.
With the increasing demand for non-surgical aesthetic procedures, the FDA's recent clearance of an ultrasound device to tighten sagging skin has come as great news to consumers, especially those in Southeast Michigan, home to one of the first of these Ulthera Systems in the nation.
A dramatic sea-change in research into ten so-called "neglected diseases," such as malaria, leprosy and sleeping sickness, could result in at least eight new drugs being developed by 2010.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Ian Kirven, PT, DPT 1156 N Main St, Sheridan, WY 82801-3055 Ph: (509) 847-4303 | Ian Kirven, PT, DPT 1156 N Main St, Sheridan, WY 82801-3055 Ph: (307) 763-4556 |
News Archive
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.
ExonHit Therapeutics (Paris:ALEHT) together with Toulouse University Hospital and l'Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT). The study's main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of cognitive functions in aged and frail individuals.
With the increasing demand for non-surgical aesthetic procedures, the FDA's recent clearance of an ultrasound device to tighten sagging skin has come as great news to consumers, especially those in Southeast Michigan, home to one of the first of these Ulthera Systems in the nation.
A dramatic sea-change in research into ten so-called "neglected diseases," such as malaria, leprosy and sleeping sickness, could result in at least eight new drugs being developed by 2010.
› Verified 4 days ago
Haley Kathleen Baltz, MS PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 50 W 3rd St, Sheridan, WY 82801 Phone: 307-672-2092 Fax: 307-673-1969 | |
Katie Ligocki, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 51 E 1st St, Sheridan, WY 82801 Phone: 307-461-1550 | |
Bret E Zowada, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 50 W 3rd St, Sheridan, WY 82801 Phone: 307-672-2092 Fax: 307-673-1969 | |
Talk Sprouts, Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 30 N Gould St Ste 4000, Sheridan, WY 82801 Phone: 804-519-2845 | |
Forge Physio & Performance Llc Physical Therapist Medicare: Medicare Enrolled Practice Location: 350 A St, Sheridan, WY 82801 Phone: 307-620-8172 Fax: 833-487-1072 | |
Jamie Ann Gillenwater, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 50 W 3rd St, Sheridan, WY 82801 Phone: 307-672-2092 Fax: 307-673-1969 |